1. Home
  2. ADAM vs DCTH Comparison

ADAM vs DCTH Comparison

Compare ADAM & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adamas Trust Inc.

ADAM

Adamas Trust Inc.

N/A

Current Price

$6.01

Market Cap

702.0M

Sector

Technology

ML Signal

N/A

DCTH

Delcath Systems Inc.

N/A

Current Price

$14.32

Market Cap

578.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADAM
DCTH
Founded
2003
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
702.0M
578.4M
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
ADAM
DCTH
Price
$6.01
$14.32
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$11.50
★ $24.00
AVG Volume (30 Days)
★ 1.0M
262.9K
Earning Date
10-28-2026
11-09-2026
Dividend Yield
★ 18.35%
N/A
EPS Growth
★ 196.49
107.53
EPS
N/A
★ 0.04
Revenue
N/A
N/A
Revenue This Year
N/A
$24.61
Revenue Next Year
$8.59
$24.27
P/E Ratio
★ $7.53
$351.75
Revenue Growth
N/A
N/A
52 Week Low
$6.55
$8.12
52 Week High
$10.36
$17.42

Technical Indicators

Market Signals
Indicator
ADAM
DCTH
Relative Strength Index (RSI) 19.31 42.11
Support Level N/A $14.26
Resistance Level $9.36 $16.51
Average True Range (ATR) 0.31 0.53
MACD -0.09 -0.01
Stochastic Oscillator 5.00 29.33

Price Performance

Historical Comparison
ADAM
DCTH

About ADAM Adamas Trust Inc.

Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: